Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Replicor Inc.

www.replicor.com

Latest From Replicor Inc.

Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis

The latest developments in one of the US FDA's favorite pathways.

Review Pathway Drug Review

Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

In Hep B, Functional Cure Likely Means Two-Part Combination Process

While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.

Infectious Diseases Clinical Trials

Hep B Cure May Lie In Reducing Surface Antigen

Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination approach to curing chronic hepatitis B. One of the leaders in this approach, Arbutus, is working toward its own internal combo therapy for the virus.

Infectious Diseases Liver & Hepatic
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Replicor Inc.
  • Senior Management
  • Jean-Marc Juteau, PhD, CEO
    Marcia T Ruiz, PhD, Dir., Pharmaceutical Dev.
    Luc Paquet, VP, R&D
  • Contact Info
  • Replicor Inc.
    Phone: (450) 688-6068
    500, Cartier Blvd. West, Ste. 135
    Laval, H7V 5B7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register